Johns Hopkins-backed biopharmaceutical developer Allakos has filed for a $75m initial public offering after raising more than $160m in equity funding.

AbbVie Ventures co-led the round having done the same for the immunotherapy developer's last round, in 2017.

The sports media platform has now raised $93m, after raising series D funds from investors including Liberty Media and Emil Capital.

Foxconn and MediaTek contributed to a $75.7m round that speech recognition technology provider AISpeech will use for hiring and product development.

Avexis, which is commercialising research from Ohio State University and Nationwide Children's Hospital, has been acquired by Novartis for $8.7bn.

The drug developer, which is targeting chronic inflammation-related diseases, has raised series A cash two years after it spun out of Selvita.

UC Investment Office-backed gene expression technology developer Constellation Pharmaceuticals has filed for an $86.3m initial public offering.

Duke Management Company and Osage University Partners have invested in the genome editing technology spinout from Duke University.

SR One-backed gene expression technology developer Constellation Pharmaceuticals has filed for an $86.3m initial public offering.

Roche and Novo-backed biopharmaceutical developer Allakos has filed for a $75m initial public offering after raising more than $160m in equity funding.